Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s ...

Rani Therapeutics Holdings (RANI) has grabbed attention after announcing a collaboration and license agreement with Chugai Pharmaceutical for an oral rare disease therapy. The deal includes payments ...

Rani Therapeutics is focused on enabling the oral delivery of biologic drugs, which are medications typically given by injection due to their complexity and sensitivity. Its main technology, the ...

The company will receive an upfront payment of $10 million. It could also earn up to $75 million in development milestones, $100 million in sales milestones, and single-digit royalties on future ...

SAN JOSE, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral ...

Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit ...

South Cone Investments Limited Partnership, a ten percent owner of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI), sold 5,923,000 shares of Class A Common Stock on October 20 and 21, 2025, for a total ...